









Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  201 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
CD97 (CD97 molecule) 
Gabriela Aust 
University of Leipzig, Faculty of Medicine, Research Laboratories, Center of Surgery, Liebigstr. 20, Leipzig, 
D-04103, Germany 
Published in Atlas Database: October 2007 
Online updated version: http://AtlasGeneticsOncology.org/Genes/CD97ID996ch19p13.html  
DOI: 10.4267/2042/38519 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 








DNA contains 27.322 kb composed of 20 coding 
exons. Exons 1-2 encode the 5' untranslated region and 
the signal peptide, exons 3-7 the five EGF domains, 
exons 8-13 the extracellular stalk, exons 14-18 the 
seven-span transmembrane (TM7) domains and exons 
19-20 the intracellular part and the 3' untranslated 
region. 
Transcription 
3247 bp mRNA transcribed in telomeric to centromeric  
orientation; 2508 bp open reading frame. Human CD97 
exists in three isoforms that result from alternative 
splicing of exons 5 and 6 and thus contain different 
numbers of EGF domains in the extracellular part of 
the molecule. The isoforms are designated as CD97 
(EGF1,2,5), CD97 (EGF1,2,3,5) and CD97 (EGF1-5) 
in human. 
Pseudogene 
No pseudogenes reported. 
Protein 
Description 
CD97 belongs to the B family of G protein-coupled 
receptors (GCPRs). Subfamily B2 contains cell surface 
molecules with long extracellular N-termini (LNB-
TM7) known also as adhesion class of heptahelical 
receptors. 
 
Genomic organization of CD97 (drawn to scale), boxes represent exons. 
 
 
Structure of CD97. Three isoforms containing 3, 4, or 5 EGF domains exist. N-glycosylation sites in the EGF domains are indicated. 
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CD97 is the founding member of a small subfamily 
within the adhesion class called EGF-TM7 family. All
EGF-TM7 receptors (CD97, EMR1, EMR2, EMR3, 
EMR4) consist of extracellular tandemly arranged EGF 
domains, a stalk, the seven-span transmembrane (TM7) 
und a short intracellular part. They are expressed as 
heterodimers of a non-covalently bound alpha- and 
beta-chain resulting from intracellular autocatalytic 
cleavage at a conserved GCPR proteolytic site (GPS). 
The alpha-chain represents the extracellular region with 
the varying numbers of EGF domains and the main part 
of the stalk and the beta-chain consists of the stalk 
residue, the TM7 and intracellular part. 
Three CD97 isoforms containing 3, 4 or 5 EGF 
domains are described. The mature full length proteins 
contain either 722, 766 or 815 amino acids (aa). After 
cleavage the (secretory) alpha-chains contain 420, 64, 
or 513 aa. The beta-chain theoretically contains 305 aa 
with a molecular weight of 34.3 kDa. However, 
immunoprecipitation of the beta-chain yielded a 
molecular weight of approximately 28 kDa. The 
discrepancy between the theoretical and actual 
molecular weight of the beta-chain is not yet clarified. 
Depending on the cell type and transformation statu of 
the cell, CD97 is completely or partly N-glycosylated 
or naked. In normal muscle cells CD97 is not or only 
slightly N-glycosylated. The molecular weight for the 
respective naked alpha-chain of the various CD97 
isoforms are 45.6, 50.5 and 55.8 kDa. In hematopoetic 
cells CD97 is N-glycosylated at the EGF domains 
resulting in molecular weights of 74-78, 80-82, and 86-
89 kDa for the alpha-chains of the respective isoform. 
During tumor transformation CD97 may get N-
glycosylated. Although the CD97 stalk contains many 
Ser or Thr residues the molecule seems not to be O-
glycosylated. 
Expression 
Broad, not cell-type specific. 
- Hematopoetic system: strong in peripheral blood 
myeloid cells and activated lymphocytes, moderately in 
subsets of tissue-derived leukocytes; 
- Strong in smooth muscle cells (except for arterial 
vascular smooth muscle cells), skeletal muscle cells 
(stronger in slow-twitch fibers), heart muscle cells; 
- Fat cells; 
- Low in normal intestinal, thyroidal epithelial cells, 
moderately in duct cells of the pancreas, parotis gland 
and in bile duct cells of the liver. 
Localisation 
Usually at the cell membrane; soluble CD97 (sCD97) 
representing the CD97 alpha-chain in body fluids;  
Skeletal muscle cells: at the sarcolemm and 
intracellularly in the sacroendoplasmatic reticulum 
(SR). 
Function 
CD97 has the ability to bind cellular and extracellular 
matrix ligands. The first two EGF domains of CD97 
bind CD55 (decay accelerating factor). The fourth EGF 
domain of CD97 and thus only the longest CD97 
isoform interacts with the glycosaminoglycan 
chondroitin sulfate B. CD97 binds to alpha5beta1 and
alphavbeta3 integrins through interaction with the 
CD97 stalk region. 
- Hematopoetic cells: Functional studies indicate a role 
of CD97 in leukocyte trafficking. CD97 antibodies 
block tissue localization of immune cells in vivo 
leading to impaired protection against bacteria and 
amelioration of autoimmune pathology. 
- Tumor cells: In vitro CD97 increases single cell 
random motility and directed migration and invasion of 
tumor cells in 2D and 3D matrices. CD97 enhances 
proteolytic activity of matrix metalloproteinases 
(MMPs) and secretion of chemokines in an isoform-
specific manner. CD97 (EGF 1,2,5) overexpression 
promotes tumor growth in scid mice. 
The alpha-chain of the longest CD97 (EGF1-5) isoform 
(sCD97) enhances angiogenesis in in vivo tumor 
models. 
- Muscle, fat, duct cells: function unknown. 
Homology 
H. sapiens: CD97  
P. troglodytes: CD97  
B. taurus: CD97  
S. scrofa: CD97  
C. lupus: CD97  
M. musculus: CD97  
R. norvegicus: CD97  




Note: Note for all tumors:  
Antibodies to various epitopes of CD97 vary strongly 
in their staining pattern and cross-reactivity to other 
EGF-TM7 molecules. The first group of monoclonal 
antibodies, which includes BL-Ac/F2, VIM-3b and 
CLB-CD97/1, binds to the EGF domains of CD97 
(CD97EGF/ antibodies). These antibodies also detect 
EMR2, another member of the EGF-TM7 family. In 
most cases, this cross-reactivity will not influenc the 
results obtained for CD97 staining in tumors since 
EMR2 is strongly restricted to myeloid cells. CD97 
antibodies MEM-180 and CLB-CD97/3 bind to the 
stalk region of CD97 (CD97stalk) and do not bind 
EMR2. 
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CD97EGF epitope accessibility depends on cell type-
specific N-glycosylation (see above). CD97EGF 
antibodies detect only N-glycosylated CD97. During 
tumor transformation, not only the CD97 protein 
expression level but also the degree of CD97 N-
glycosylation varies. Thus, the selection of the CD97 
antibody strongly influences the result in 
immunohistological studies focused on the correlation 
between CD97 and histopathological subtypes, 
diagnosis, progression, or prognosis of tumors. 
CD97 in tumors is strongly regulated at the post-
trancriptional level. 
Thyroid cancer 
Note: In normal thyroid tissue, no or low 
immunoreactivity of CD97 is found. In differentiated 
follicular thyroid carcinoma or papillary thyroid 
carcinoma, CD97 expression is also either lacking or 
low. Most undifferentiated anaplastic carcinomas 
reveal high CD97 presentation. CD97 is absent or only
weakly present in patients with postoperative T1 
tumors but increased greatly with the progression to 
postoperative T4 tumors. Until now, only antibodies 
against CD97 EGF domains (CD97EGF antibodies, see 







Overexpression of CD97 might be important for the 
progression of thyroid cancer. 
Colorectal cancer 
Note: Normal human colorectal epithelium is slightly 
CD97-positive. Most colorectal carcinomas express 
CD97. The strongest staining for CD97 occurs in 
scattered tumor cells at the invasion front compared to 
cells located within solid tumor formations of the same 
tumor. Carcinomas with more strongly CD97-stained 
scattered tumor cells show a poorer clinical stage s 
well as increased lymph vessel invasion compared to 






Overexpression of CD97 might be important for 
invasion and metastasis of colorectal cancer. 
Gastric cancer 
Note: CD97 is present in normal parietal cells of  
 
gastric mucosa. It is stronger expressed by most gastric 
carcinomas. Half of the tumors show scattered tumor 
cells at the invasion front with stronger CD97 







Note: Normal smooth muscle cells are CD97-positive. 
In this cell type CD97 is not N-glycosylated. Thus, 
monoclonal antibodies that detect an N-glycosylation 
dependent epitop of CD97 do not react with normal 
smooth muscle cells (CD97EGF antibodies). During 
transformation CD97 get partly N-glyocosylated in 
most uterine leiomyoma and or completely N-
glyocosylated in nearly 25% of the leiomyosarcomas. 
These tumors are now positive for CD97EGF antibodies. 
However, one third of leiomyosarcomas are completely 
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